The drug that could

SORAFENIB was first approved by the US Food and Drug Administration (FDA) for advanced renal carcinoma, or kidney cancer.

In October 2007, it was approved by the European Commission for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. It is the first approved systemic therapy for HCC and the only one shown to significantly improve overall survival in patients with the disease.